Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsBruce Strober, MD, PhD, FAAD
Clinical ProfessorAbout
Research
Publications
2026
Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Strober B, Augustin M, Tada Y, Lafferty K, Krol Y, Skobelev E, Ibrahim F, Fakharzadeh S, Gniadecki R. Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of Psoriasis And Psoriatic Arthritis 2026, 24755303261477021. PMID: 42602014, PMCID: PMC13473216, DOI: 10.1177/24755303261477021.Peer-Reviewed Original ResearchEffectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review
Armstrong A, Strober B, Liu C, Cather J, Merola J, Lebwohl M. Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review. Journal Of Dermatological Treatment 2026, 37: 2694924. PMID: 42581417, DOI: 10.1080/09546634.2026.2694924.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDeucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials
Armstrong A, Lebwohl M, Warren R, Morita A, Paul C, Thaçi D, Augustin M, Puig L, Daamen C, Li J, Alió A, Aggrey-Amable A, Scotto J, Popmihajlov Z, Vaile J, Strober B. Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials. American Journal Of Clinical Dermatology 2026, 27: 1071-1089. PMID: 42563042, PMCID: PMC13578007, DOI: 10.1007/s40257-026-01055-w.Peer-Reviewed Original ResearchBridging Psoriasis and Metabolic Comorbidities: Toward Comprehensive Patient Management. Priorities from the International Psoriasis Council
Strober B, Treichel A, Bowcock A, Cooper K, Gisondi P, González-Cántero Á, Lambert J, Liao W, López-Ferrer A, Mehta N, Skov L, van de Kerkhof P, Gelfand J. Bridging Psoriasis and Metabolic Comorbidities: Toward Comprehensive Patient Management. Priorities from the International Psoriasis Council. Journal Of The American Academy Of Dermatology 2026 PMID: 42501796, DOI: 10.1016/j.jaad.2026.07.066.Peer-Reviewed Original ResearchRapid resolution of generalized pustular psoriasis with upadacitinib
Mistry S, Marchitto M, Strober B. Rapid resolution of generalized pustular psoriasis with upadacitinib. JAAD Case Reports 2026, 75: 161-164. PMID: 42571487, PMCID: PMC13452361, DOI: 10.1016/j.jdcr.2026.07.006.Peer-Reviewed Original ResearchMatching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis
Crowley J, Song E, Stein-Gold L, Gisondi P, Bunick C, Garg V, Leoncini E, Kaplan B, Ta R, Truong B, Sharma D, Strober B. Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology And Therapy 2026, 16: 4139-4153. PMID: 42393457, PMCID: PMC13493357, DOI: 10.1007/s13555-026-01839-2.Peer-Reviewed Original ResearchIxekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity
Lebwohl M, Blauvelt A, Kartman C, Leatherwood C, Gordon K, Sattar N, Puig L, Merola J, Siu K, Wang R, Sun L, Leung A, Somani N, Rueda M, Cardoso A, Genovese M, Armstrong A, Strober B. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity. JAMA Dermatology 2026, 162: 709-719. PMID: 42139049, PMCID: PMC13179568, DOI: 10.1001/jamadermatol.2026.1753.Peer-Reviewed Original ResearchSummary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial
Langley R, Arkin L, Fiorillo L, Eichenfield L, Lebwohl M, Strober B, Sticherling M, Swanson L, Kokolakis G, Chaudhari S, Deignan C, Zhang Z, Paller A. Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial. Dermatology And Therapy 2026, 16: 2229-2232. PMID: 42133282, PMCID: PMC13219672, DOI: 10.1007/s13555-026-01714-0.Peer-Reviewed Original ResearchEnvudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review
Armstrong A, Krueger J, Strober B, Stein Gold L, Desai S, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley M, Blauvelt A. Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review. Dermatology And Therapy 2026, 16: 2661-2673. PMID: 41934538, PMCID: PMC13237387, DOI: 10.1007/s13555-026-01727-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsReply to Woodie et al, “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX”
Torres T, Blauvelt A, Strober B, van de Kerkhof P, Eakin G, Winthrop K, Gelfand J. Reply to Woodie et al, “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX”. Journal Of The American Academy Of Dermatology 2026, 95: e71-e72. PMID: 41850622, DOI: 10.1016/j.jaad.2025.12.129.Commentaries, Editorials and Letters